NEW YORK (GenomeWeb News) - ADA Technologies said today that it has received a $149,121 grant from the National Cancer Institute to develop a nanotechnology-based imaging and sensing platform for discovering cancer biomarkers.
ADA said it is developing a sensing platform for analyzing biomolecules, such as cancer biomarkers, “that is more sensitive than existing technologies,” but did not disclose further details of the technology.
The company, based in Littleton, Colo., is a research, development, and commercialization firm that works in a range of technologies and application areas. Its R&D efforts related to nanotechnology imaging and sensing platforms began in 2007.